BIOGNOSYS
Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, and Kymera Therapeutics, a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD), announced today that they are broadly collaborating across preclinical studies and clinical trials.
Proteome editing with TPD is a new frontier of medicine, aimed at expanding the druggable proteome. Biognosys’ TrueSignature™ platform uniquely offers high-precision proteomic panels that provide actionable insights based on highly specific and sensitive, absolute quantification of pharmacodynamic and efficacy biomarkers. These custom panels allow Kymera to monitor and quantify protein degradation. The ease of transferability of the assays — from early discovery, across preclinical evaluation, to clinical development — enables integration into all stages of Kymera’s drug development process . The panels are developed and performed at Biognosys’ state-of-the-art facility, the largest high-end, GLP certified and GCP compliant mass spectrometry laboratory worldwide for large-scale proteomics contract research.
“Kymera’s novel approach to targeted protein degradation is a great example of the power of proteomics-enabled drug development,” said Kristina Beeler, Ph.D., Chief Business Officer of Biognosys . “We are glad to see the impact our TrueSignature platform is having, not only on the advancement of Kymera’s clinical trial programs, but also on patients’ lives.”
The current partnership between Kymera and Biognosys builds upon the longstanding scientific relationship between the two companies across early R&D, preclinical, and clinical settings across oncology and inflammation.
“Biognosys has been a valued partner as we continue to expand our clinical pipeline across a diverse set of diseases and indications,” said Nello Mainolfi, Ph.D., Co-Founder, President and CEO, Kymera Therapeutics . “The company’s high-precision custom proteomics panels enable us to monitor and quantify protein degradation across all aspects of drug development, including preclinical and clinical programs.”
About TrueSignature™
The Biognosys TrueSignature™ platform provides high-precision customizable proteomics panels for pharmacodynamic readouts and clinical biomarker monitoring.
Parallel Reaction Monitoring mass-spectrometry powers the platform, allowing complete customization and independence from affinity-based recognition and reagent availability. The TrueSignature™ panels offer an unprecedented level of multiplexing, enabling the simultaneous absolute quantification of up to 100 proteins.
TrueSignature panels can be developed within weeks and are available both as a standalone solution or an integrated solution, in which insights from TrueDiscovery studies guide the choice of proteins in the custom panel. The measurements are performed with unprecedented speed and throughput at Biognosys' state-of-the-art facility, the world's largest high-end GLP-certified and GCP-compliant mass spectrometry laboratory. For more information, visit truesignature.bio
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions, and making them widely available for pharmaceutical and biotechnology researchers, and proteomics experts. The company offers a versatile portfolio of proprietary proteomics services, software, and kits, including the TrueDiscovery™, TrueTarget™, and TrueSignature™ platforms and flagship software Spectronaut™. These solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. For more information, visit biognosys.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005156/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TOURISE Reframes Tourism Sector as Global Powerhouse on a Path to $16 Trillion During Davos24.1.2026 00:22:00 CET | Press release
TOURISE advanced tourism’s role as a vital sector connecting industries, economies, and regions to address shared global challenges at the World Economic Forum Annual Meeting in Davos. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123950180/en/ His Excellency Ahmed Al‑Khateeb, Minister of Tourism of Saudi Arabia and Chairman of TOURISE, convenes executives from Trip.com, Visa, TikTok, PayPal, Salesforce, Forbes, Avolta, ByteDance, and more at Davos 2026 Often overlooked as a siloed industry, TOURISE pressed the importance of tourism being recognized as a strategic sector, contributing one in every $10 to global GDP and uplifting every industry it touches. His Excellency Ahmed Al Khateeb, Minister of Tourism of Saudi Arabia and Chairman of TOURISE said alliances and collaboration across sectors will see tourism continue to rise. “Tourism is more than a lifestyle sector, it functions as a strategic economic system. TOURISE
Zycus Named a Leader in the 2026 Gartner® Magic Quadrant™ for Source-to-Pay Suites23.1.2026 20:00:00 CET | Press release
This acknowledgment reflects Zycus’ momentum in Agentic AI, comprehensive S2P suite, brand trust and customer outcomes. Zycus, a global provider in Source-to-Pay (S2P) technology, today announced that it has been recognized as a Leaderin the 2026 Gartner® Magic Quadrant™ for Source-to-Pay Suites. We believe the report points to Zycus’ continued investment in Merlin Intake to streamline user experience and Agentic AI to support workflows such as tail-spend management via autonomous negotiation. This aligns with Zycus’ “Intake to Outcomes” (I2O) belief: simplify how work enters procurement, orchestrate execution with Agentic AI, and deliver outcomes with the right governance and control. “Being recognized as a Leader in the Gartner Magic Quadrant for Source-to-Pay Suites reflects our long-term commitment to innovation, customer outcomes, and responsible AI,” said Aatish Dedhia, Founder & CEO of Zycus. “Merlin Agentic AI is designed to move beyond task automation towards end-to-end outcom
Bureau Veritas to Acquire a Leading Sustainability Specialist for Consumer Products in Italy23.1.2026 18:13:00 CET | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), announces the acquisition of SPIN360, a leading Italian consulting firm specialized in sustainable innovation and development across primary premium fashion and luxury brands. This acquisition aligns with Bureau Veritas’ LEAP | 28 strategy to create new strongholds in the Consumer Product Services (CPS) industry, and to accelerate its growth in key markets such as Italy. The transaction will deliver on value creation opportunities, by combining SPIN360's proprietary Life Cycle Assessment (LCA) tools and data-driven advisory services with Bureau Veritas' certification and supply chain auditing expertise. It will also help position Bureau Veritas as a global center of excellence for premium fashion and luxury. Created in 2009 and based in Milan, SPIN360 provides technical advisory services covering LCA, life cycle costing, environmental product declarations, carbon footprint, supply chain engagement
HCLTech to Acquire Singapore-based Finergic to Boost Digital Transformation Offerings for Wealth Management Industry23.1.2026 17:55:00 CET | Press release
HCLTech, a leading global technology company, today announced that it has signed a definitive agreement to acquire Finergic Solutions Pte Ltd, a boutique wealth consulting firm headquartered in Singapore. The transaction is expected to close by April 30, 2026. Founded in 2019, Finergic focuses on core banking and wealth management transformation and has a strong, well-established global presence. The addition of Finergic’s niche capabilities, combined with the scale of HCLTech, is expected to unlock stronger synergies and enhance service delivery across the financial services and wealth management industry. HCLTech brings 25+ years of global experience in serving leading financial institutions. By integrating Finergic’s specialized transformation strategy, consulting and wealth-architecture capabilities, HCLTech will accelerate the delivery of next-generation, platform-enabled wealth management solutions anchored by advanced AI-native workflows. These capabilities will complement HCLTe
Saudi Arabia to Host World Economic Forum Global Collaboration and Growth Meeting: Building Common Ground and Reviving Growth on 22-23 April 202623.1.2026 16:29:00 CET | Press release
Saudi Arabia will host the World Economic Forum (WEF) Global Collaboration and Growth Meeting: Building Common Ground and Reviving Growth in Jeddah on 22-23 April 2026, it was announced on the closing day of the 56th Annual Meeting of the Forum in Davos, Switzerland. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123725881/en/ HE Faisal F. Alibrahim, Saudi Arabia’s Minister of Economy and Planning, announces that the Kingdom will host the World Economic Forum Global Collaboration and Growth Meeting in Jeddah in April 2026 (Photo: AETOSWire) His Excellency Faisal F. Alibrahim, Saudi Arabia’s Minister of Economy and Planning today confirmed the details for the regular high-level WEF meeting, which was announced at the 2025 WEF Annual Meeting. Calling for pragmatism and collaboration against a backdrop of geopolitical fragmentation, HE Alibrahim said “stability can’t be quickly built, and it can’t be bought”. “Stability need
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom